On May 11 after the market closed, AcelRx Pharmaceuticals (NASDAQ:ACRX) reported 1Q20 earnings. The stock did not move much from the event, but investors that have been following the company for some time now finally got a piece of news they had been waiting for.
ACRX is a specialty pharmaceutical company with two products: Zalviso and DSUVIA (US)/DZUVEO ("EU").
Product Portfolio
Source: March 2020 presentation (slide 6)
DSUVIA is a sublingual sufentanil tablet that comes in a pre-filled, single-dose applicator ("SDA"). It is approved in both the US and EU for the management